| Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis T Kirchhausen, E Macia, HE Pelish Methods in enzymology 438, 77-93, 2008 | 489 | 2008 |
| Mediator kinase inhibition further activates super-enhancer-associated genes in AML HE Pelish, BB Liau, II Nitulescu, A Tangpeerachaikul, ZC Poss, ... Nature 526 (7572), 273-276, 2015 | 367 | 2015 |
| Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product HE Pelish, NJ Westwood, Y Feng, T Kirchhausen, MD Shair Journal of the American chemical society 123 (27), 6740-6741, 2001 | 294 | 2001 |
| Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro HE Pelish, JR Peterson, SB Salvarezza, E Rodriguez-Boulan, JL Chen, ... Nature chemical biology 2 (1), 39-46, 2006 | 195 | 2006 |
| Identification of mediator kinase substrates in human cells using cortistatin A and quantitative phosphoproteomics ZC Poss, CC Ebmeier, AT Odell, A Tangpeerachaikul, T Lee, HE Pelish, ... Cell reports 15 (2), 436-450, 2016 | 142 | 2016 |
| An alkylsilyl-tethered, high-capacity solid support amenable to diversity-oriented synthesis for one-bead, one-stock solution chemical genetics JA Tallarico, KM Depew, HE Pelish, NJ Westwood, CW Lindsley, ... Journal of combinatorial chemistry 3 (3), 312-318, 2001 | 138 | 2001 |
| Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components JR Peterson, AM Lebensohn, HE Pelish, MW Kirschner Chemistry & biology 13 (4), 443-452, 2006 | 82 | 2006 |
| The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes KM Marks, ES Park, A Arefolov, K Russo, K Ishihara, JE Ring, J Clardy, ... Journal of natural products 74 (4), 567-573, 2011 | 48 | 2011 |
| Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation II Nitulescu, SC Meyer, QJ Wen, JD Crispino, ME Lemieux, RL Levine, ... EBioMedicine 26, 112-125, 2017 | 47 | 2017 |
| NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation HE Pelish, A Tangpeerachaikul, NE Kohl, JR Porter, MD Shair, JC Horan Cancer Research 81 (13_Supplement), 1468-1468, 2021 | 32 | 2021 |
| Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading B Xu, H Pelish, T Kirchhausen, GB Hammond Organic & biomolecular chemistry 4 (22), 4149-4157, 2006 | 32 | 2006 |
| STAT3 inhibitory activity of structurally simplified withaferin A analogues T Tahara, U Streit, HE Pelish, MD Shair Organic letters 19 (7), 1538-1541, 2017 | 19 | 2017 |
| The Cdc42 inhibitor secramine B prevents cAMP-induced K+ conductance in intestinal epithelial cells HE Pelish, W Ciesla, N Tanaka, K Reddy, MD Shair, T Kirchhausen, ... Biochemical pharmacology 71 (12), 1720-1726, 2006 | 16 | 2006 |
| NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations A Drilon, JC Horan, A Tangpeerachaikul, B Besse, SHI Ou, SM Gadgeel, ... Cancer discovery 13 (3), 598-615, 2023 | 14 | 2023 |
| NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation HE Pelish, A Tangpeerachaikul, NE Kohl, JR Porter, MD Shair, JC Horan Cancer Research 81 (13_Supplement), 1465-1465, 2021 | 4 | 2021 |
| Alkaloids M Shair, N Westwood, HE Pelish US Patent 6,797,819, 2004 | 4 | 2004 |
| Preclinical activity of NVL-655 in ALK-driven cancer models beyond non-small cell lung cancer A Tangpeerachaikul, L Bigot, L Friboulet, HE Pelish Cancer Res 82 (12_Supplement), 3337, 2022 | 3 | 2022 |
| Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC A Tangpeerachaikul, A Deshpande, NE Kohl, JC Horan, HE Pelish Molecular Cancer Therapeutics 20 (12_Supplement), P244-P244, 2021 | 3 | 2021 |
| PRPK-TPRKB modulators and uses thereof ES Park, HE Pelish, AS Clarke, GL Williams, MP Castaldi, A Arefolov, ... US Patent 9,193,989, 2015 | 3 | 2015 |
| Biomimetic combinatorial synthesis M Shair, C Lindsley, H Pelish, S Sheehan, B Goess, M Layton, L Chan, ... US Patent App. 09/838,760, 2001 | 3 | 2001 |
